

<u>IN THE UNITED STATES PATENT AND TRADEMARK OFFICE</u>

Application Number

09/898,750

Confirmation No.:

7451

Applicant

Wetmur, James G., et al.

Filed

: July 03, 2001

Title

NUCLEIC ACID DISPLACER COMPOSITIONS AND CELLS

COMPRISING SAME

TC/Art Unit

To be Assigned

Examiner:

To be Assigned

RECEIVED

Docket No.

Enz-49(P2)(C)

OCT 1 4 2004

Customer No.

21967

OFFICE OF PETITIONS

Mail Stop: Petition

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

PETITION FOR REVIVAL OF AN APPLICATION FOR PATENT ABANDONED UNINTENTIONALLY UNDER 37 CFR 1.137(b)

Sir,

The above-identified application became abandoned for failure to file a timely and proper reply to a "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures", mailed August 08, 2001 (hereinafter "the Notice"). The date of abandonment is October 08, 2001 (*i.e.*, the day after the expiration date of the period set for reply in the Notice).

Applicant hereby petitions for revival of this application. As required, this Petition includes herewith: (1) Petition Fee; (2) Required Reply; and (3) Statement that the entire delay was unintentional.

Applicant includes herein the Petition Fee, under 37 C.F.R. § 1.17(m). Applicant claims

small entity status.



10/12/2004 FFANAEIA 00000006 09898750

14 66.1482

1370.00

Attorney Docket Number Enz-49 (P2)(C)
Application Serial Number 09/898,750
October 08, 2004

The Reply to the above-noted Notice is enclosed herewith in the form of a Response to notice to comply with requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures (hereinafter "the required reply").

As this utility application was filed after June 8, 1995, no terminal disclaimer is required.

Applicant hereby states that the entire delay in filing the required reply from the due date for the reply until the filing of a grantable petition pursuant to 37 C.F.R. § 1.137(b) was unintentional.

Respectfully submitted,

HUNTON & WILLIAMS LLP

Dated: October 8, 2004

By:

Robert M. Schulman Registration No. 31,196 Robert C. Lampe III Registration No. 51,914

HUNTON & WILLIAMS LLP 1900 K Street, N.W. Washington, D.C. 20006 Telephone (202) 955-1500 Fax: (202) 778-2201



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patient and Trademark Office Address COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vignia 22313-1450 www.uspto.gov

APPLICATION NUMBER

FILING OR 371(C) DATE

FIRST NAMED APPLICANT

ATTY. DOCKET NO./TITLE

09/898,750

07/03/2001

James G. Wetmur

Enz-49(P2)(C)

Ronald C. Fedus, Esq. Enzo Therapeutics, Inc. c/o Enzo Biochem, Inc. 527 Madison Avenue, 9th Floor

New York, NY 10022

CONFIRMATION NO. 7451 ABANDONMENT/TERMINATION **LETTER**

OC000000012867116*

OCT 1 4 2004

OFFICE OF PETITIONS Date Mailed: 06/04/2004

NOTICE OF ABANDONMENT UNDER 37 CFR 1.53 (f) OR (g)

The above-identified application is abandoned for failure to timely or properly reply to the Notice to File Missing Parts (Notice) mailed on 08/08/2001.

· No reply was received.

A petition to the Commissioner under 37 CFR 1.137 may be filed requesting that the application be revived.

Under 37 CFR 1.137(a), a petition requesting the application be revived on the grounds of UNAVOIDABLE DELAY must be filed promptly after the applicant becomes aware of the abandonment and such petition must be accompanied by: (1) an adequate showing of the cause of unavoidable delay; (2) the required reply to the aboveidentified Notice; (3) the petition fee set forth in 37 CFR 1.17(I); and (4) a terminal disclaimer if required by 37 CFR 1.137(d).

Under 37 CFR 1.137(b), a petition requesting the application be revived on the grounds of UNINTENTIONAL DELAY must be filed promptly after applicant becomes aware of the abandonment and such petition must be accompanied by: (1) a statement that the entire delay was unintentional; (2) the required reply to the aboveidentified Notice; (3) the petition fee set forth in 37 CFR 1.17(m); and (4) a terminal disclaimer if required by 37 CFR 1.137(d).

Any questions concerning petitions to revive should be directed to the "Office of Petitions" at (703) 305-9282. Petitions should be mailed to: Mail Stop Petitions, Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

A copy of this notice MUST be returned with the reply.

Customer Service

Initial Patent kamination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE







ED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231 www.uspto.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/898,750

Ronald C. Fedus, Esq. Enzo Therapeutics, Inc.

c/o Enzo Biochem, Inc.

New York, NY 10022

527 Madison Avenue, 9th Floor

07/03/2001

James G. Wetmur

Enz-49(P2)(C)

CONFIRMATION NO. 7451

FORMALITIES LETTER

OC000000006398425

RECEIVED

OCT 1 4 2004

OFFICE OF PETITIONS Date Mailed: 08/08/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES**

-Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

 This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov



Customer Service Center
Initial Patent Examination Division (703) 308-1202
PART 1 - ATTORNEY/APPLICANT COPY







United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NUMBER

FILING OR 371 (c) DATE

FIRST NAMED APPLICANT

ATTY. DOCKET NO./TITLE

09/898,750

07/03/2001

James G. Wetmur

Enz-49(P2)(C)

Ronald C. Fedus, Esq. Enzo Therapeutics, Inc. c/o Enzo Biochem, Inc. 527 Madison Avenue, 9th Floor New York, NY 10022



CONFIRMATION NO. 7451
RESEND COVER LETTER
OC00000010719576

Date Mailed: 08/19/2003

COVER LETTER FOR RESENDING CORRESPONDENCE

A courtesy copy of the Notice mailed on 08/08/2001 is enclosed. The time period for reply continues to run from the mail date of that Notice.

OFFICE OF PETITIONS

A copy of this notice <u>MUST</u> be returned with the reply.